FDA published the draft guidance "Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing" on April 14 under docket number FDA-2026-D-1255, with comments due July 14, 2026. [1] Wednesday is Day Nine of the 90-day window. The docket is open; the Center for Biologics Evaluation and Research has no scheduled public meeting. Industry responses — from Vertex, CRISPR Therapeutics, Editas, Beam, Intellia and Prime Medicine — remain in drafting, according to regulatory counsel who track CBER filings.

The paper's Tuesday brief opened the clock on this framework as the first operational CRISPR document since the January 2024 umbrella guidance on "Human Gene Therapy Products Incorporating Human Genome Editing." [2] Wednesday holds the clock and adds substance. The guidance recommends sponsors detect low-frequency off-target editing events with "an appropriate sequencing strategy that meets the goals of the on-target and off-target assessments" and flags DNA double-strand breaks and medium-to-large insertions or deletions as the genomic-integrity cases requiring additional NGS. FDA Commissioner Marty Makary, who put his name on the release, said the agency is "serious about moving this ball forward." [3]

The operational read: this is CBER telling small sponsors which sequencing depth, sample selection and analysis parameters the agency expects, not what therapies it will approve. It is a methods document that could shorten INDs for rare-disease programs, assuming the comment window does not produce substantive pushback. Day Nine has produced no filed comment. Eighty-three days remain.

-- NORA WHITFIELD, Chicago